- Active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome
This study is testing a new medicine, Deucravacitinib, for adults with an active form of Sjögren's Syndrome. Researchers want to see if it's safe and effective compared to a dummy pill. It's a key step to finding better treatments for this autoimmune condition.
For: Sjögren's SyndromeUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus
This study is looking at a new medicine called deucravacitinib to see if it's safe and helps people with a type of lupus called Systemic Lupus Erythematosus (SLE). It compares the new medicine to a dummy pill (placebo).
For: Systemic Lupus ErythematosusUnited States · Argentina · Australia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Severe Plaque Psoriasis
This study looks at a new medicine called deucravacitinib for people with moderate to severe plaque psoriasis. It aims to see if it's safe and effective over a long period. This is a follow-up study for people who have already tried the medicine.
For: Moderate-to-Severe Plaque PsoriasisHungary · Germany · Sweden - Ongoing, recruitingTherapeutic use (Phase IV)
A Phase 4 Multicenter, Randomized, Open-label, Efficacy Assessor-blinded-Study of Risankizumab Compared to Deucravacitinib for the Treatment of Adult Subjects with Moderate Plaque Psoriasis who are Candidates for Systemic Therapy
This study is looking at two medicines, risankizumab and deucravacitinib, for adults with moderate plaque psoriasis. It compares how well they clear up skin and aims to see if switching medicine helps if the first one isn't working as well as hoped.
For: Plaque PsoriasisHungary · Germany · Greece - Active not recruitingPHASE3
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
This study is looking at a new medicine, JNJ-77242113, for people with moderate to severe plaque psoriasis. It compares how well it works against a dummy treatment (placebo) and an existing medicine called deucravacitinib.
For: Plaque PsoriasisUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
This study is looking at a new medicine called deucravacitinib for people with active psoriatic arthritis who haven't tried certain other strong medicines for their condition before. It aims to see how well it works and if it's safe.
For: Psoriatic ArthritisUnited States · Argentina · Australia - RecruitingPHASE3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
This study compares a new medicine, deucravacitinib, with an existing one, ustekinumab, for long-term safety in people with moderate to severe plaque psoriasis. It focuses on participants who also have heart disease risk factors.
For: Plaque PsoriasisUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment
This study is testing a new medication called deucravacitinib for active psoriatic arthritis. It compares the new drug to a dummy pill to see if it helps people feel better and if it's safe. It's for people new to certain treatments or who have tried one specific type before.
For: Psoriatic ArthritisUnited States · Argentina · Australia - RecruitingPHASE3
A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants With Moderate to Severe Plaque Psoriasis
This study is looking at a new medicine called deucravacitinib for children and teenagers aged 4 to 17 with moderate to severe plaque psoriasis. It aims to understand how much medicine is needed, if it works, and if it's safe to use.
For: Plaque PsoriasisArgentina · Australia · Brazil